A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Recruiting · Phase 1 · NCT05303467
Conditions: Glioblastoma Multiforme, Recurrent Glioblastoma
At a glance
- Research payments reported, 2025
- $1.6M
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 36
About the trial
- Sponsor
- Boston Scientific Corporation
- Tested
- TheraSphere GBM (device)
- Dates
- Started 2022-07-30; completion 2027-06-30
- Results posted
- Not yet
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
From ClinicalTrials.gov, last updated 2026-10-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Boston Scientific Corporation reported $1.6M in research payments for this study in 2025 (54 payments).
Products named: Clinical Trial Product
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nicholas A. Butowski, MD Neurosurgery · San Francisco, CA
- Alfredo Quinones-hinojosa, MD Neurosurgery · Jacksonville, FL
- Clifford R. Weiss, M.D. Radiology · Baltimore, MD
- John Boockvar, MD Neurosurgery · Brooklyn, NY
- Samdeep Mouli, M.D. Interventional Radiology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Northwestern University $1.1M
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $312,237
- Mayo Clinic $152,678
- Johns Hopkins University $29,037
- The Feinstein Institute for Medical Research $13,396
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.